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Abstract
Background:  Pregnancy-related pelvic pain is a common condition, and use of hormonal
contraceptives before pregnancy has been proposed as a risk factor. We used data from a sub-
sample of women participating in the "Norwegian Women and Cancer study" (NOWAC) to assess
the association between hormonal contraceptive use and pelvic pain in pregnancy.
Methods:  From a sub-group of 2078 parous women participating in the NOWAC study,
information was collected from a self-instructive four-page questionnaire containing questions
about lifestyle and medical conditions. We calculated odds ratios (OR) and 95% confidence
intervals (CI), using unconditional logistic regression.
Results: In this study, the prevalence of pelvic pain in women was 26.5% during the first pregnancy
and increased with parity. Use of hormonal contraceptives before a woman's first pregnancy was
associated with an increased risk of pelvic pain in her first pregnancy (OR = 1.6; 95% confidence
interval 1.2–2.2). There was no association between use of hormonal contraceptives and pelvic pain
in the second or third pregnancy. Occurrence of pelvic pain in a previous pregnancy was the only
factor associated with pelvic pain in subsequent pregnancies (OR = 51.1; 95% CI 32.9–79.5 in the
second pregnancy and OR = 28.3; 95% CI 15.4–53.1 in the third pregnancy).
Conclusion: Use of hormonal contraceptives was associated with an increased risk of pelvic pain
in a woman's first pregnancy. The most important determinant of pelvic pain in the second or third
pregnancy was the history of pelvic pain in the preceding pregnancy.
Background
The first documented description of pelvic pain in preg-
nancy was published by Snelling in the American Journal
of Medicine in 1870 [1]. However, it is believed that
Hippocrates recognized the disease among pregnant
women in Ancient Greece as far back as 400 BC. Pelvic
pain in pregnancy is one of the many terms used to
describe a collection of typical symptoms [2-5]. Other
terms used in scientific literature are: low back pain [6-8],
back pain [3,9-11], backache [12] and symphysial pain
[10]. In Norway this condition is termed "bekkenløsn-
ing". This word incorporates pregnancy-related low back
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pain and pelvic pain. The symptoms vary in strength from
discomfort to complete immobilization. Several studies
have indicated that pelvic pain in pregnancy is a wide-
spread, and possibly increasing, health problem among
women in industrialized countries [7,9,13-15]. The prev-
alence of pelvic pain in pregnancy varies between 25–50%
in different studies [7-9,12]. Several risk factors for this
condition have been hypothesized, such as age, parity,
education, back pain before pregnancy, type of employ-
ment, body size, smoking habits, and use of hormonal
contraceptives [2].
We present here results from a study of pelvic pain in preg-
nancy in relation to hormonal contraceptive use before
the first pregnancy and between pregnancies.
Methods
Study population
The "Norwegian Women and Cancer study" (NOWAC)
was implemented between 1991 and 1997. A total of
179,388 women from 30–70 years of age were invited to
participate, and 102,443 agreed [16]. All women were
sampled randomly from the national population register
of Norway. This register records the addresses of all per-
sons alive and residing in the country, and the dates of
death or migration to and from Norway since 1960. In
this register, each person is identified by a unique 11-digit
national registration number. The first six digits encode
information on the date of birth, and the last five digits
use an algorithm to ensure a unique number, and include
information on gender [17]. Health survey questionnaires
were mailed to women in batches for convenience. In
1991–2, as part of NOWAC, a four-page questionnaire
was mailed to a batch of 4,000 women born between
1943 and 1957 (35–49 years of age). Women who did not
return the questionnaire in a few weeks were mailed a
reminder with an identical letter of introduction and
questionnaire. The questionnaires were returned to the
Institute of Community Medicine in Tromsø, Norway.
The questionnaire assessed lifestyle characteristics, repro-
ductive history, including number and duration of each
pregnancy, prevalent diseases, and other different medical
conditions, including pelvic pain during each pregnancy.
We asked about the occurrence of pregnancy-related pel-
vic pain (Did you suffer from pelvic pain in any of your
pregnancies?) and the grade or severity of the symptoms
during each of the first three pregnancies (severe disabil-
ity, problems with walking, painful walking, problems in
doing housework, normal physical function level). We
used the severity question to classify pelvic pain in the first
three pregnancies. Hormonal contraceptives were intro-
duced on the Norwegian market in 1967. Questions
about hormonal contraceptive use were summary meas-
ures (as ever having used, total estimated overall duration
of use, and use before first pregnancy) with detailed ques-
tions for each period of use, such as age when use began,
brand used, age when use was interrupted, and duration
of use. A folder with photos of almost all the 36 hormonal
contraceptive brands that have ever been on the Norwe-
gian market was enclosed with the questionnaire to help
women to recall use of these drugs.
Data analysis
From the 4,000 women randomly selected for this sub-
study we excluded 52 women who had emigrated, were
dead at the time the questionnaire was sent, or had a
severe mental handicap. Altogether 2,400 women agreed
to participate in the study and returned a completed ques-
tionnaire, giving a crude response rate of 60.0 % or a cor-
rected response rate of 60.8%. Of these, 2,188 women
reported at least one pregnancy lasting six months or
more.
We further excluded 35 women due to a lack of informa-
tion on the use of hormonal contraceptives and 75
women who did not answer the question about pelvic
pain. Thus, 2,078 women were included in the final anal-
ysis presented here.
We registered twin pregnancies as one pregnancy. We clas-
sified hormonal contraceptives in two ways. Firstly, all
hormonal contraceptives – regardless of the mode of
administration (oral or injectable), and hormonal con-
tent (combined estrogen-progestin contraceptives, and
medroxyprogesterone acetate only pills or injections) –
were considered together. Secondly, we classified contra-
ceptives according to the hormonal content as progestin-
only contraceptives, and combined estrogen-progestin
contraceptives. We classified women as having used hor-
monal contraceptives before the first pregnancy, before
second pregnancy (regardless if the use was only before
first pregnancy, both before first pregnancy and between
first and second pregnancy, or only between first and sec-
ond pregnancy) and before third pregnancy (as for the
second pregnancy, but also including women using con-
traceptives between the second and third pregnancies).
The statistical analyses were performed using the SAS sta-
tistical package version 8.12. Logistic regression was used
for the estimation prevalence of odds ratios (OR) with
95% confidence intervals (CI). Analyses were done sepa-
rately for each of the three first pregnancies.
In the multivariate analysis, besides use of hormonal con-
traceptives before each relevant pregnancy, we included in
the models the following co-variables hypothesized to be
associated with pregnancy-related pelvic pain: time
elapsed since relevant birth, weight of the newborn in
each relevant pregnancy and age at menarche. In theBMC Pregnancy and Childbirth 2004, 4 http://www.biomedcentral.com/1471-2393/4/11
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analysis of pelvic pain in the first pregnancy we also
included indicator variables for potential risk factors in
the multivariate regression models, namely education,
height of the mother and smoking habits during the first
pregnancy. However, since they did not affect the risk esti-
mates meaningfully, they were excluded in the multivari-
ate analysis of the second and third pregnancies.
For the analysis of the second and third pregnancies we
considered the occurrence of pelvic pain in the previous
pregnancy as potential determinants of pelvic pain in the
following pregnancy.
Results
Characteristics of the study participants
Some characteristics of the women included in the study
are shown in Table 1. The age distribution in the study
population was nearly uniform, while use of hormonal
contraceptives before first pregnancy decreased with
increasing age at enrolment. Women who reached
menarche before age 14 were more likely to have used
Table 1: Characteristics of the study population (n = 1163)
Study cohort Number (%) Used hormonal contraceptives 
before first birth
% p value
Age
35–36 years 320 (15.4) 49.1
37–38 years 273 (13.1) 49.5
39–40 years 276 (13.3) 42.4
41–42 years 296 (14.2 27.4
43–44 years 260 (12.5) 20.4
45–46 years 296 (14.2) 15.5
4949 years 357 (17.2) 10.9 p < 0.0001
Age at menarche
< = 12 year 538 (26.4) 30.1
13 years 615 (30.2) 35.5
> = 14 years 882 (43.3) 26.6 p = 0.001
Age at first birth
<= 20 years 503 (24.2) 6.4
21–25 years 961 (46.3) 25.6
> = 26 years 614 (29.5) 57.0 p<= 0.0001
Weight of newborn child
-3000 g 360 (18.0) 31.4
30001–3500 g 750 (37.4) 31.2
3501–4000 g 617 (30.8) 28.4
> = 4001 g 276 (13.8) 31.9 P = 0.6
Education
7–9 years 428 (20.9) 12.9
10–12 years 759 (37.2) 24.2
13–15 years 517 (25.3) 39.9
> = 16 years 339 (16.6) 51.9 p < 0.0001
Years between menarche and first birth
0–5 years 215(10.6) 5.6
6–10 years 926(45.5) 17.4
11–15 years 628 (30.9) 43.0
> = 16 years 266 (13.1) 64.7 p < 0.0001
Number of births
One 307(14.8) 46.3
Two 1044 (50.2) 32.2
Three 543 (26.1) 23.9
> = Four 184(8.9) 10.9 p < 0.0001
Smoking in the first pregnancy
No 1396 (69.6) 30.5
Yes 611 (30.4) 30.0 p = 0.8BMC Pregnancy and Childbirth 2004, 4 http://www.biomedcentral.com/1471-2393/4/11
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hormonal contraceptives before their first pregnancy than
women over 14 years of age at menarche (p = 0.001). Age
at first birth, years of education, and interval between
menarche and first birth were directly associated with hor-
monal contraceptive use before first pregnancy (p values
< or = 0.001). The inverse was observed with number of
births (p < 0.001). Use of hormonal contraceptives before
first pregnancy was unrelated with weight of the first new-
born child (p = 0.60). Nearly one-third of the women
smoked during their first pregnancy. The proportion of
hormonal contraceptive users before first pregnancy was
similar among smokers and non-smokers.
Pelvic pain in pregnancy
Pregnancy-related pelvic pain – in the first, second or third
pregnancy – was reported most often in the youngest
women in our study (data not shown). The proportion of
women reporting pregnancy-related pelvic pain increased
with the number of pregnancies (22.9% in the first preg-
nancy, 27.4% in the second pregnancy and 34.0% in the
third pregnancy). Similar increase in the prevalence of
pelvic pain with increasing number of pregnancies was
observed in all age groups, irrespective of age at study
enrolment (data not shown).
Pelvic pain in the first pregnancy
Women who reported having used hormonal contracep-
tives before their first pregnancy reported a higher fre-
quency of pelvic pain in the first pregnancy as compared
with non-users (OR = 1.6; 95% CI 1.2–2.1) (Table 2). Nei-
ther age at menarche, age at first birth, time elapsed since
first birth; weight of newborn child, years of education
nor smoking during the first pregnancy changed signifi-
cantly the risk estimated in this analysis (Table 2).
Pelvic pain in the second and third pregnancies
Use of hormonal contraceptives before second and before
third pregnancy was not associated with risk of preg-
nancy-related pelvic pain in the second or third pregnancy
(OR = 1.0; 95% CI 0.7–1.5 and OR = 1.2; 95% CI 0.7–1.9
respectively). The only important determinant of preg-
nancy-related pelvic pain in the second or third pregnancy
was the history of pregnancy-related pelvic pain in the
preceding pregnancy (OR = 57.3; 95% CI 40.5–81.2 in
second pregnancy and OR = 31.2; 95% CI 19.7–49.4 in
third pregnancy) (Table 3). Pregnancy-related pelvic pain
in the second pregnancy (but not in the first) was a strong
predictor of pelvic pain in the third pregnancy (RR 18.0,
95% CI 8.2–39.6). Women who presented pregnancy-
related pain in the first two pregnancies had an extremely
high risk of also suffering from it in the third pregnancy
(RR 232, 95% CI 82–658).
Table 2: Odds ratio (OR) with 95% confidence intervals (CI) for pregnancy-related pelvic pain in the first pregnancy
Characteristic Pregnancy-related pelvic pain in first pregnancy
OR (95% CI) *
Use of hormonal contraceptives before first birth
No 1.0 (ref.)
Yes 1.6 (1.2–2.1)
Age at menarche
<= 12 years 1.0 (ref.)
13 years 0.9 (0.7–1.2)
14 + years 0.8 (0.6–1.1)
Age at first birth
< = 20 years 1.0 (ref.)
21–25 years 1.2 (0.9–1.5)
26 + years 0.8 (0.5–1.1)
Time elapsed since first birth (per 3 years)** 0.9 (0.8–1.0)
Weight of newborn child (per 500 g) 1.0 (0.95–1.1)
Years of education
7–9 1.0 (ref.)
10–12 1.0 (0.7–1.3)
13–15 0.9 (0.7–1.3)
16+ 1.1 (0.7–1.7)
Smoking during first pregnancy
No 1.0 (ref.)
Yes 0.9 (0.7–1.1)
* All variables are mutually adjusted. Analysis includes women with valid information for listed variables, i.e. 437 women with and 1424 women 
without pregnancy-related pelvic pain during their first pregnancy. ** Years between first birth and enrolment in the study cohort.BMC Pregnancy and Childbirth 2004, 4 http://www.biomedcentral.com/1471-2393/4/11
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We found no clear association between duration of use of
hormonal contraceptives before first pregnancy and preg-
nancy-related pelvic pain in the first pregnancy (Test for
heterogeneity p = 0.23). There was no evidence of a differ-
ential effect according to the hormonal content of the pill,
i.e., progestin- only or combined estrogen-progestin pills
(Test for heterogeneity p = 0.94) (Table 4).
We also performed an analysis classifying separately the
23 women that used both progestin-only and combined
estrogen-progestin contraceptives. In this analysis the esti-
Table 3: Relative risk (RR) with 95% confidence intervals (CI) for pregnancy-related pelvic pain in the second and third pregnancies 
according to history of previous pregnancy (ies)
Characteristic Pregnancy-related pelvic pain in second 
pregnancy
Pregnancy-related pelvic pain in third 
pregnancy
RR (95% CI)* RR (95% CI)**
Pregnancy-related pelvic pain in first pregnancy
No 1.0 (ref.) -
Yes 57.3 (40.5–81.2) -
Pregnancy-related pelvic pain in at least one of 
the first two pregnancies
No - 1.0 (ref.)
Yes - 31.2 (19.7–49.4)
Not suffered from Pregnancy-related pelvic 
pain in the previous two pregnancies
1.0 (ref)
Pregnancy-related pelvic pain -
in the first but not in the second pregnancy - 1.4 (0.5–4.0)
not in the first but in the second pregnancy - 18.0 (8.2–39.6)
both in the first and the second pregnancy - 232 (82–659)
* Adjusted for use of hormonal contraceptives, age at second birth, weight of newborn and time since second birth (years between second birth 
and enrolment in the study cohort). Analysis includes women with valid information for listed variables, i.e., 467 women with and 1221 women 
without pregnancy-related pelvic pain in second pregnancy. ** Adjusted for use of hormonal contraceptives, age at third birth, weight newborn and 
time since third birth (years between third birth and enrolment in the study cohort). Analysis includes women with valid information for listed 
variables, altogether 233 women with and 449 women without pregnancy-related pelvic pain during their second pregnancy.
Table 4: Odds ratio (OR) with 95% confidence intervals (CI) for pregnancy-related pelvic pain in the first pregnancy
Characteristic N Pregnancy-related pelvic pain in first 
pregnancy
OR (95 % CI)*
No use 1290 1.0 (ref.)
Duration of hormonal contraceptives 
before first pregnancy**
1–29 months 245 1.8 (1.3–2.5)
30–59 months 135 1.2 (0.8–1.9)
60 months or more 135 1.6 (1.0–2.5)
Type of hormonal contraceptives used 
before first pregnancy***
Progestin-only contraceptives 71 1.7 (0.97–2.8)
Combined estrogen-progestin 
contraceptives****
323 1.7 (1.2–2.3)
* Adjusted for age at menarche, years of education, smoking during first pregnancy, age at first birth, weight of newborn and time since first birth 
(years between first birth and enrolment in the study cohort). **Analysis includes women with valid information for duration and adjustment 
variables, i.e. 421 women with and 1384 without pregnancy related pelvic pain in first pregnancy. ***Analysis includes women with valid information 
for brand name and adjustment variables, i.e. 387 women with and 1297 without pregnancy related pelvic pain in first pregnancy. **** Includes 23 
women who used both progestin-only and combined contraceptives before first pregnancy.BMC Pregnancy and Childbirth 2004, 4 http://www.biomedcentral.com/1471-2393/4/11
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mates were equal as those in the Table 4 for progestin-
only and for combined estrogen-progestin contraceptives,
and the estimate for women who used both was OR = 2.0
(95% CI: 0.8–5.0). Finally, we excluded from the analysis
these 23 women, and the results were not materially dif-
ferent than those shown in Table 4.
Discussion
In our study use of hormonal contraceptives was associ-
ated with the occurrence of pelvic pain in the first preg-
nancy, but not in the second and third pregnancies.
Occurrence of pelvic pain in a previous pregnancy was
strongly associated with occurrence of the symptoms in
subsequent pregnancies.
During a fertile life, at least 20% of women experience pel-
vic pain in at least one pregnancy. The prevalence of the
symptoms increases with increasing parity [2,9,12]. Most
of the published studies on determinants of pregnancy-
related pelvic pain originate from Scandinavia, where this
condition appears to be prevalent [2,3,9,10,13,18,19].
Only a few studies have looked into hormonal contracep-
tives as a possible risk factor for pregnancy-related pelvic
pain [3,6,7,9,14]. All these studies were negative or non-
conclusive, and most of them were too small to allow any
conclusions. None of them have stratified the analysis on
parity, analysing each pregnancy separately. Our strategy
of analysing each pregnancy separately might explain why
our results deviate from earlier studies. If hormonal con-
traceptives are an explanatory biological factor in the
development of pelvic pain, it might be an advantage to
study each pregnancy separately, because of the high
recurrence of the condition in subsequent pregnancies.
Endresen [2] emphasises that both age and parity are
important explanatory variables, out of which parity is the
more powerful. She also argues that adjustment for age
would hardly be required if the data were stratified for
parity.
Östgaard et al. [11] reported that back problems inde-
pendent of pregnancy was an important factor when pre-
dicting back pain and pain intensity in a future pregnancy.
We did not have information about back pain before preg-
nancy in our study, and thus we could not take this factor
into consideration in our analyses.
The response rate in this study was around 60%, which
might be considered low. The possible problems with a
low response rate, such as selection bias, have been dis-
cussed elsewhere [20]. It is unlikely that the response rate
introduced a selection bias that might cause major prob-
lems in this study. The unique person-number given to all
Norwegian inhabitants made it possible for us to link a
sub-sample of the women in the Norwegian Women and
Cancer Study to the National Register of Education and
Fertility and compare the responses with the total invited
group in the same sub-cohort. This linkage uncovered no
selection bias except that the response rate increased with
increased education. We have slightly better educated
women in the cohort than expected according to the Nor-
wegian female population as a whole [16]. In addition, no
association between the proportion of women using hor-
monal contraceptives, parity or age at first birth was
revealed according to the response rate from an earlier
analysis within our same study cohort [21]. If ever users of
hormonal contraceptives with pelvic pain were more
likely to answer the questionnaire than never users of hor-
monal contraceptives without pelvic pain, selection bias
could have occurred. We consider this to be rather
unlikely, since a possible association between hormonal
contraceptive use and pregnancy-related pelvic pain was
not a known hypothesis in the general population at the
time of the survey. Moreover, the questions about preg-
nancy-related pelvic pain were not mentioned in the
study's letter of introduction or in the headings of the
questionnaires used.
Differential misclassification of exposure [22] could have
resulted in either an exaggerated or underestimated effect.
However, we have no reason to believe that women with
a history of pelvic pain systematically remembered their
hormonal contraceptive use differently from women
without this condition.
Our study could have been affected by recall bias: women
might remember in more detail recent events (such as
recent use of hormonal contraceptives or pain related to a
recent pregnancy) compared to past events. Time elapsed
since first birth is correlated with the woman's birth year,
and we found a non-significant reduced risk of pregnancy-
related pelvic pain with increasing time elapsed since first
birth. However, if pelvic pain incidence is increasing,
younger women or women who gave birth for the first
time close to enrolment will be more likely to report hav-
ing suffered from the illness. Both the association between
pelvic pain and women's birth year or age have been
reported earlier [2,9].
Conclusions
Our results suggest that use of hormonal contraceptives
before the first pregnancy may cause an increased risk of
pregnancy-related pelvic pain in the first pregnancy. Preg-
nancy-related pelvic pain in a preceding pregnancy is a
very strong predictor of pelvic pain in a subsequent
pregnancy.
The association between use of hormonal contraceptives
and pelvic pain in the first pregnancy is this study was
weak, but it might be of interest in a public health per-
spective since both the prevalence of hormonal contracep-Publish with BioMed Central    and   every 
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tive use before first pregnancy, and the prevalence of
pelvic pain in pregnancy are high in Scandinavia.
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